-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atrial fibrillation is a major risk factor for acute ischemia stroke and can be disabling and fatal.
In secondary prevention, oral anticoagulants (OACs) are the most effective way to prevent relapsed ishemotic strokes and systemic embolisms in stroke patients and atrial fibrillation patients.
, OACs can also lead to an increased risk of bleeding, especially in the brain.
with cerebrovascular disease associated with bleeding tendencies, the risk of cerebral hemorrhage-related cerebral hemorrhage is higher.
micro-bleeding (CMBs) is often thought to be a sign of bleeding-prone vascular lesions.
for atrial fibrillation patients who were treated with OACs after an ishedic stroke (AIS) were evaluated for the impact of recent CMBs studies on their future hemorrhagic stroke.
these studies showed that in patients taking OACs after AIS, the presence of a baseline of CMBs was independently associated with an increased risk of hemorrhagic stroke.
, however, found that the risk of prospective hemorrhagic stroke was very low.
In fact, the recurrence rate of ischemic stroke and vascular death caused by systemic embolism caused by atrial fibrillation is much higher than the rate of OACs-related hemorrhagic stroke, even in CMBs patients.
, however, the impact of CMBs on clinical outcomes in AIS and AF patients taking OACs has not been fully studied.
Kang-Ho Choi of All-South University Hospital in South Korea and others studied the presence, burden and location of micro-bleeding in patients with acute ishemia stroke and atrial fibrillation treated with OAC on the risk of major adverse cerebrovascular and cardiovascular events.
, they also looked at whether the clinical effectiveness of CMBs varies depending on the type of OACs.
they included 1,742 AIS and atrial fibrillation patients treated with OACs, with the main results being to observe macCE (stroke, myocardial infarction, or a combination of vascular death) during 2 years of follow-up.
results show that the presence of CMB is significantly related to future MACCE risk after adjusting for the mixing factors (HR=1.89; p = 0.003)。
patients with 1 CMB had a MACCE ratio similar to that of patients without CMBs (p s 0.461).
and multiple CMBs (≥2), especially in patients with high-load CMBs (≥5), significantly higher MACCE than in the control group (p .lt; 0.05).
the CMB-positive group MACCE frequency was higher than that of the CMB-negative group, and the occurrence rate of MACCE was not significantly different from the CMB position.
in patients treated with huafalin, CMB was significantly associated with MACCE risk (p s 0.002), but not in patients treated with direct OACs (p s 0.517).
The main significance of this clinical study of nearly 2,000 people was to find that in patients with AIS and atrial fibrillation taking OACs, the risk of future MACCE increased as the CMB load increased, while the anatomical location of CMBs did not affect the risk of future MACCE.
risk appears to be more pronounced in patients taking wahfalin.
Choi, KH, Kim, JH, Lee, C., Kim, JM, Kang, KW, Kim, JT, ... & Cho, KH (2020). Microbleeds and Outcome in Patients With Acute Ischemic Stroke and Atrial Fibrillation Taking Anticoagulants. Stroke , 51 (12), 3514-3522.<!--5f39ae17-8c62-4a45-bc43-b32064c9388a: W3siYmxvY2tJZCI6IjU1NzctMTYwOTg4Mzg3NzQ3MCIsImJsb2NrVHlwZSI6InBhcmFncmFwaCIsInN0eWxlcyI6eyJhbGlnbiI6ImxlZnQiLCJpbmRlbnQiOjAsInRleHQtaW5kZW50IjowLCJsaW5lLWhlaWdodCI6MS43NSwiYmFjay1jb2xvciI6IiIsInBhZGRpbmciOiIifSwidHlwZSI6InBhcmFncmFwaCIsInJpY2hUZXh0Ijp7ImRhdGEiOlt7ImNoYXIiOiJTIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6InQiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoiciIsInN0eWxlcyI6e yJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiJvIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6ImsiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoiZSIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiItIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IuaKlyIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLlh50iLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0sey JjaGFyIjoi5rK7Iiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IueWlyIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLnmoQiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi5LitIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IumjjiIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLmgqMiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi6ICFIiwic3R5bGV zIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6Iu+8jCIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLohJEiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi5YaFIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IuW+ riIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLlsI8iLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi5Ye6Iiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IuihgCIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLkvJoiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi5piOIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IuaYviIsInN0eWxlcyI6eyJiYWNrL WNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLlop4iLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi5YqgIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IuW/ gyIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLohJEiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi6KGAIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19LHsiY2hhciI6IueuoSIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fSx7ImNoYXIiOiLnlr4iLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiNmZmZmZmYifX0seyJjaGFyIjoi55eFIiwic3R5bGVzIjp7ImJhY2stY29sb3IiOiIjZmZmZmZmIn19XSwiaXNSaWNoVGV4dCI6dHJ1ZSwia2VlcExpbmVCc mVhayI6dHJ1ZX19LHsiYmxvY2tJZCI6IjQwMTctMTYwOTg4NTE4ODg3OCIsImJsb2NrVHlwZSI6InBhcmFncmFwaCIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiIiwiYWxpZ24iOiJsZWZ0IiwiaW5kZW50IjowLCJ0ZXh0LWluZGVudCI6MCwibGluZS1oZWlnaHQiOjEuNzUsInBhZGRpbmciOiIifSwidHlwZSI6InBhcmFncmFwaCIsInJpY2hUZXh0Ijp7ImRhdGEiOlt7ImNoYXIiOiLCoCIsInN0eWxlcyI6eyJiYWNrLWNvbG9yIjoiI2ZmZmZmZiJ9fV0sImlzUmljaFRleHQiOnRydWUsImtlZXBMaW5lQnJlYWsiOnRydWV9fSx7ImJsb2NrSWQiOiI4Nj I0LTE2MDk4ODUxODg4NzgiLCJibG9ja1R5cGUiOiJwYXJhZ3JhcGgiLCJzdHlsZXMiOnsiYmFjay1jb2xvciI6IiIsImFsaWduIjoibGVmdCIsImluZGVudCI6MCwidGV4dC1pbmRlbnQiOjAsImxpbmUtaGVpZ2h0IjoxLjc1LCJwYWRkaW5nIjoiIn0sInR5cGUiOiJwYXJhZ3JhcGgiLCJyaWNoVGV4dCI6eyJkYXRhIjpbXSwiaXNSaWNoVGV4dCI6dHJ1ZSwia2VlcExpbmVCcmVhayI6dHJ1ZX19LHsiYmxvY2tJZCI6Ijk0OTMtMTYwOTg4NTE4ODA0OCIsImJsb2NrVHlwZSI6InBhcmFncmFwaCIsInN0eWxlcyI6eyJhbGlnbiI6ImxlZnQiLCJpbmRlbnQ iOjAsInRleHQtaW5kZW50IjowLCJsaW5lLWhlaWdodCI6MS43NSwiYmFjay1jb2xvciI6IiIsInBhZGRpbmciOiIifSwidHlwZSI6InBhcmFncmFwaCIsInJpY2hUZXh0Ijp7I
